Enanta Pharma (ENTA) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to Enanta Pharma (ENTA) Misses Q3 EPS by 1c

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018

August 7, 2018 4:01 PM EDT

Webcast and Conference Call today at 4:30 p.m. ET

Royalty revenue for the quarter increased to $57.3 million, a quarter-to-quarter increase of 30% Net income was $20.3 million, or $0.97 per diluted common share Preliminary Phase 1 results demonstrate that RSV candidate EDP-938 was generally safe and well tolerated and support its progression to Phase 2 Cash and marketable securities totaled $295.5 million at June 30, 2018

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a... More